Regeneron Pharmaceuticals Inc. buy SVB Securities
Start price
27.03.23
/
50%
€769.90
Target price
27.03.24
€905.83
Performance (%)
16.25%
End price
28.03.24
€895.00
Summary
This prediction ended on 28.03.24 with a price of €895.00. The BUY prediction by SVB_Securities finished with a performance of 16.25%. SVB_Securities has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 3.320% | 3.320% | 0.529% |
| iShares Core DAX® | 3.002% | 3.742% | 24.169% |
| iShares Nasdaq 100 | 2.966% | 1.308% | 9.141% |
| iShares Nikkei 225® | 5.606% | 4.472% | 21.237% |
| iShares S&P 500 | 2.312% | 1.880% | 6.333% |
Comments by SVB_Securities for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at SVB Securities from a "market perform" rating to an "outperform" rating. They now have a $976.00 price target on the stock, up previously from $834.00.
Ratings data for REGN provided by MarketBeat
In the thread Trading Regeneron Pharmaceuticals Inc.
Die von SVB_Securities gewählte maximale Laufzeit wurde überschritten